that GaMF1 inhibitsATPsynthase activity by binding to the loop. GaMF1 is bactericidal and is active against multidrug‐ as well as bedaquiline‐resistant strains. Chemistry efforts on the scaffold revealed a dynamic structure activity relationship and delivered analogues with nanomolar potencies. Combining GaMF1 with bedaquiline or noveldiarylquinoline analogues showed potentiation without inducing genotoxicity
F 1 F O -ATP合酶是结核分枝杆菌生长和生存力所必需的并且是经过验证的临床目标。酶旋转γ亚基的分枝杆菌特异性环在酶复合物中ATP合成的偶联中起作用。我们报告发现了针对这种γ亚基环的新型抗分枝杆菌GaMF1的发现。生化和NMR研究表明,GaMF1通过与环结合来抑制ATP合酶活性。GaMF1具有杀菌作用,对多药耐药和苯达喹啉耐药菌株具有活性。在支架上的化学努力揭示了动态结构活性关系,并提供了具有纳摩尔浓度的类似物。GaMF1与苯达喹啉或新型二芳基喹啉类似物的结合在人胚胎干细胞报告基因分析中显示出增强作用,而不会引起基因毒性或表型变化。
[EN] COMPOUNDS FOR TREATING TUBERCULOSIS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE LA TUBERCULOSE
申请人:UNIV NANYANG TECH
公开号:WO2018151681A1
公开(公告)日:2018-08-23
The present invention relates to pyrimidine compounds and compositions for treating tuberculosis. These compounds may be used to target the F1 domain of F-ATP synthase and may be used with bedaquiline or 6-chloro-2-ethyl-N-[[4-[4- [4-(trifluoromethoxy)phenyl]piperidin-1 -yl]phenyl]methyl]imidazo[1,2-a]pyridine-3-carboxamide (Q203) or a combination thereof.
HIV-1 assembly and disassembly (uncoating) processes are critical for the HIV-1replication. HIV-1 capsid (CA) and human cyclophilin A (CypA) play essential roles in these processes. We designed and synthesized a series of thiourea compounds as HIV-1 assembly and disassembly dual inhibitors targeting both HIV-1 CA protein and human CypA. The SIV-induced syncytium antiviral evaluation indicated that
Colour and constitution of azo compounds derived from diaminoazines
作者:Michael G. Hutchings、Barry H. Meyrick、Anthony J. Nelson
DOI:10.1016/s0040-4020(01)91257-8
日期:1984.1
Visible absorption spectra have been recorded for azo compounds derived from 2,5-dichlorosulphanilic acid azo-coupled with ,-diethyl-m-phenylenediamine, and with azine analogues. The effects of the ring-aza substituents as well as cyano on the spectra indicate a surprising difference in sensitivity of the two ring positions meta to the azo group. M.O. calculations show chat the amino group ortho to
The present invention relates to pyrimidine compounds and compositions for treating tuberculosis. These compounds may be used to target the F1 domain of F-ATP synthase and may be used with bedaquiline or 6-chloro-2-ethyl-N-[[4-[4-[4-(trifluoromethoxy)phenyl]piperidin-1-yl]phenyl]methyl]imidazo[1,2-a]pyridine-3-carboxamide (Q203) or a combination thereof.